



A Mini Review on Biological Activities and synthetic approaches for 1,3,4-Oxadiazoles

Authors & Affiliation:

Ahmed Ibrahim Hameed¹
Mujahid Alam^{2*}

¹Head Department, Ministry of Oil
 NRC, Salahden-Bajji, Iraq
 Email: ahmedibr.1978@gmail.com

²Dept. of Chemistry, College of Sciences, King Khalid University, P Box 9004 Abha 61413, Saudi Arabia
 Email: mmujahidalam@gmail.com

Corresponding Author

Mujahid Alam

Email: mmujahidalam@gmail.com

Article received: 13.06.2019

Article accepted: 15.11.2019

© 2019. The Authors. Published under Caribbean Journal of Science and Technology

ISSN 0799-3757

<http://caribjscitech.com/>

Abstract:

This mini-review presents a summary of literature survey on the synthetic approaches for the preparation of 1,3,4-oxadiazoles and their derivatives. Further, various biological activities of these derivatives were also summarized.

Keywords: 1,3,4-Oxadiazoles, synthesis, biological activity

Introduction:

Oxadiazole is a heterocyclic aromatic compound consisting of 2 nitrogen atoms, 2 carbon atoms, and 1 oxygen atom with 2 double bonds in a five membered ring. It consists of four possible isomers (Figure 1), namely 1,2,3-, 1,2,4-, 1,2,5- and 1,3,4-oxadiazoles. They are one of the most valuable pharmacological, pesticide and polymeric products in heterocyclic chemistry.¹⁻³




Figure 1

The 1,3,4-oxadiazole derivatives may act as ester and amide bioisosteres and hence are of interest in pharmaceutical, agrochemical, organic light-emitting diodes (OLEDs) fields.⁴⁻⁵ Owing to possessing conjugate diene type character, electrophilic substitution at carbon is very difficult. Among four isomers, 1,3,4-oxadiazole isomer shows lower magnitude lipophilicity. This moiety is susceptible for electrophilic, nucleophilic, thermal and photochemical reactions.⁶

Biological significance of 1, 3, 4-Oxadiazoles

Several 1,3,4-oxadiazoles are found to have characteristic drug activity in related studies, makes the medicinal chemists concentrate on the preparation and pharmacological evolution of novel 1,3,4-oxadiazole derivatives.

The following are a few examples of the 1,3,4-oxadiazole derivatives consists of biological significance.

Anti-inflammatory activity

Jayashankar *et al*⁷ reported the preparation and biological evaluation of 1,3,4-oxadiazole bearing bis(heterocycle) analogues as anti-inflammatory and analgesic agents (Figure 2).




Figure 2

Antimicrobial activity

Farshori *et al*⁸ developed and synthesized oxadiazoles and thiadiazoles, were screened for antibacterial and antifungal activities (Figure 3).




Figure 3

Anti-Fungal activity

Some novel 2,5-disubstituted 1,3,4-oxadiazoles were evaluated for their *in-vitro* antifungal activity by Sangshetti *et al*⁹ (Figure 4).




Figure 4

Anti-Bacterial activity

Chandrakantha *et al*¹⁰ developed a series of new 1,3,4-oxadiazole derivatives containing 2-fluoro-4-methoxy moiety and evaluated for their antimicrobial studies (Figure 5).





Figure 5



Antioxidant activity

Musad *et al*¹¹ described the synthesis and evaluation of antioxidant and antibacterial activities of 4-[5-[[5-[4-(dimethylamino)phenyl]-1,3,4-oxadiazol-2-yl]methyl]-1,3,4-oxadiazol-2-yl]-N,N-dimethyl-aniline (Figure 6) has shown moderate antioxidant and antibacterial activity.




Figure 6

Antitumor activity

Rajak *et al*¹² developed a series of novel 2, 5-disubstituted-1,3,4-oxadiazoles/ thiadiazole as surface recognition moiety and screened for the antiproliferative activities. 2-[[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]amino]pyrimidine-5-carbohydroxamic acid (Figure 7) is found to have the best antitumor activity against Ehrlich ascites carcinoma.




Figure 7

Anticonvulsant activity

Rajak *et al*¹³ identified that 4-[5-[(E)-[(5R)-5-isopropenyl-2-methyl-cyclohex-2-en-1-ylidene] amino] carbalmoylamino]-1,3,4-oxadiazol-2-yl]phenyl] azinicacid (Figure 9) has shown remarkable anticonvulsant activity.




Figure 8

Anti-Hepatitis-B Virus activity

Tan *et al*¹⁴ discovered the synthesis and the biological evaluation of 2-benzene sulfonyl alkyl-5-substituted-sulfanyl-[1,3,4]-oxadiazoles as potential anti-hepatitis B virus agents (Figure 9).




Figure 9

Cytotoxic activity

Gurupadaswamy *et al*¹⁵ synthesized a series of 2,5-di (4-aryloylaryloxy-methyl)-1,3,4-oxadiazoles which were screened for the cytotoxicity (Figure 10).





Figure 10

Existing synthetic approaches


The synthesis of 1,3,4-oxadiazoles using various Lewis, bronsted catalysts, ionic liquids, acidic reagents has been performed. The following are the recent developments for the synthesis of 1,3,4- oxadiazoles over the recent years have been briefly discussed below

Surendra Babu *et al*¹⁶ reported the preparation and characterization of 1,3,4-oxadiazoles derivatives from 1,2,3,4-tetrahydroisoquinoline and evaluated successfully for their antibacterial & antifungal activities (Scheme 1).




Scheme 1

Guin *et al*¹⁷ developed Cu (II) catalyzed imine C-H functionalization leading to the synthesis of 2,5-substituted-1,3,4-oxadiazoles as shown in Scheme 2.




Scheme 2

Superior reactivity of thiosemicarbazides in the synthesis of 2-amino-1,3,4-oxadiazoles has been described by Dolman *et al*¹⁸ using thiosemicarbazides (Scheme 3).




Scheme 3

As shown in Scheme 4, Ramazani *et al*¹⁹ developed a new one-pot and efficient method for the synthesis of the 2,5-disubstituted 1,3,4-oxadiazole.



Scheme 4

Rivera *et al*²⁰ reported that 1,3-dibromo-5,5-dimethylhydantoin is an effective oxidizing agent for cyclization reactions of acylthiosemicarbazide (Scheme 5).




Scheme 5

Stabilea *et al*²¹ described a mild and convenient one-pot synthesis of 2-phenyl-5-substituted-1,3,4-oxadiazoles (Scheme 6).




Scheme 6


Brain *et al*²² described a novel procedure for the synthesis of 1,3,4-oxadiazoles from 1,2-diacylhydrazines using polymer-supported Burgess reagent under microwave conditions in combination with single-mode microwave heating with considerable yields (Scheme 7).

**Scheme 7**


Li and Dickson²³ developed a convenient one-pot protocol for the synthesis of 1,3,4-oxadiazoles from carboxylic acids and hydrazides as described in Scheme 8.

**Scheme 8**


Rajapakse *et al*²⁴ described a mild and efficient one pot synthesis of 1,3,4-oxadiazoles from carboxylic acids and acyl hydrazides (Scheme 9).

**Scheme 9**


Wang *et al*²⁵ described a very productive one step synthesis of 1,3,4-oxadiazoles utilizing polymer supported reagents and microwave heating from a variety of carboxylic acids and acid hydrazides in one simple step (Scheme 10).

**Scheme 10**

Li *et al*²⁶ reported that silica-supported dichlorophosphate is an efficient cyclodehydration agent for the synthesis of 2,5-disubstituted 1,3,4-oxadiazoles from 1,2-diacylhydrazines in a solvent-free medium under microwave irradiation (Scheme 11).

**Scheme 11**

Dabiri *et al*²⁷ described a facile procedure for the one-pot synthesis of unsymmetrical 2,5-disubstituted 1,3,4-oxadiazoles from the cyclizationoxidation reaction of acyl hydrazones (Scheme 12).



Scheme 12

Conclusion:

In this mini-review, authors tried to outline the synthetic approaches and biological activities of 1,3,4-oxadiazoles upto 2018. Hope this will be a valuable addition in the field of synthetic as well as medicinal chemistry.

References:

1. Bostrom. J.; Hogner. A.; Llinas. A.; Wellner. E.; Plowright. A.T.; *J. Med. Chem.* **2012**, *55*, 1817.
2. Mohan. T.P.; Vishalakshi. B.; Bhat. K.S.; Rao. K.S.; Kendappa. G.N.; *Indian J. Chem. Sect B* **2004**, *43*, 1798.
3. Schulz. B.; Kaminorz. Y.; Brehmer. L.; *Synth. Met.* **1997**, *84*, 449.
4. He. G.S.; Tan. L.-S.; Zheng. Q.; Prasad. P.N.; *Chem. Rev.* **2008**, *108*, 1245.
5. Guimaraes. C.R.W.; Boger. D.L.; Jorgensen W.L.; *J. Am. Chem. Soc.* **2005**, *127*, 17377.
6. Chhama. S.; Sanchit.S.; *J.Drug Delivery & Therapeutics.* **2015**, *5*, 8.
7. Jayashankar. B.; Lokanath Rai. K. M.; Baskaran. N.; Sathish. H. S.; *Eur. J. Med. Chem.* **2009**, *44*, 3898.
8. Farshori. N. N.; Banday. M. R.; Ahmad. A.; Khan. A. U.; Rauf. A.; *Bioorg. Med. Chem. Lett.* **2010**, *20*, 1933.
9. Ramazani. A.; Rezaei. A.; *Org. Lett.* **2010**, *12*, 2852.
10. Chandrakantha. B.; Shetty. P.; Nambiyar. V.; Isloor. N.; Isloor. A. M.; *Eur. J. Med. Chem.* **2010**, *45*, 1206.
11. Musad E. A.; Mohamed. R.; Saeed. B. A.; Vishwanath. B. S.; Lokanatha Rai. K. M.; *Bioorg. Med. Chem. Lett.* **2011**, *21*, 3536.
12. Rajak. H.; Agarawal. A.; Parmar. P.; Thakur. B. S.; Veerasamy. R.; Sharma. P. C.; Kharya. M. D.; *Bioorg. Med. Chem. Lett.* **2011**, *21*, 57358.
13. Rajak. H.; Bhupendra. S. T.; Singh. A.; Raghuvanshi. K.; Sah. A. K.; Veerasamy. R.; Sharma. P. C.; Pawar. R. S.; Kharya .M.D.; *Bioorg. Med. Chem. Lett.* **2013**, *23*, 864.
14. Tan. T. M. C.; Chen. Y.; Kong. K. H.; Bai.J.; Li. Y.; Lim. S. G.; Anga. T. H.; Lam. Y.; *Antivir. Res.* **2006**, *71*, 771.
15. Gurupadaswamy. H. D.; Girish. V.; Kavitha. C. V.; Raghavan. S. C.; Khanum. S. A.; *Eur. J. Med. Chem.* **2013**, *63*, 536.
16. Krishna. R. N.; Surendra. B.N.; Basaveswarao. M. V.; Keshavi. R.; Sundara. R. N.; Murthy. Y. L. N.; Lakshma.S. *Chem. Sci. Trans.* **2017**, *6*, 485.
17. Guin. S.; Ghosh. T.; Rout. S. K.; Banerjee. A.; Patel. B. K.; *Org. Lett.* **2011**, *13*, 5976.
18. Dolman. S. J.; Gosselin. F.; Davies. I. W.; *J. Org. Chem.* **2006**, *71*, 9548.
19. Ramazani. A.; Rezaei. A.; *Org. Lett.* **2010**, *12*, 2852.
20. Rivera. N.R.; Balsells. J.; Hansen. K.B.; *Tetrahedron Lett.* **2006**, *47*, 4889.
21. Stabilea. P.; Lamonicaa. A.; Ribecaia. A.; Castoldia.D.; Guercioa.G.; Curcurutob.O.; *Tetrahedron Lett.* **2010**, *51*, 4801.
22. Brain. C. T.; Paul. J. M.; Loong. Y.; Oakley. P. J.; *Tetrahedron Lett.* **1999**, *40*, 3275.
23. Li.C.; Dickson. H.D. A.; *Tetrahedron Lett.* **2009**, *50*, 6435.
24. Rajapakse. H. A.; Zhu. H.; Young. M. B.; Mott. B. T.; *Tetrahedron Lett.* **2006**, *47*, 4827.

25. Wang. Y.; Sauer. D. R.; Dric. S. W.; *Tetrahedron Lett.* **2006**, 47, 105.
26. Li. Z.; Zhu. A.; Mao. X.; Sun. X.; Gong. X.; *J. Braz. Chem. Soc.* **2008**, 19, 1622.
27. Dabiri. M.; Salehi. P.; Baghbanzadeh. M.; Bahramnejad.; *Tetrahedron Lett.* **2006**, 47, 6983.
28. Bhawna. S.; Amita.V.; Sunil. P.; Upendra. K. S.; *Int. J.Med. Chem.* **2013**, 2013, 348948.